Information about NationDrugs.to
List of countries where we can ship Methsuximide:
Latest news releases on Methsuximide:
Methsuximide is a succinimide with anticonvulsant properties. Although the exact mechanism of action of methsuximide is unclear, it is thought to increase the seizure threshold and suppress the paroxysmal three-cycle-per-second spike-and-wave pattern seen with absence (petit mal) seizures.
Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland) and Celontin (United States). The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer ...
Tell all of your health care providers that you take methsuximide. This includes your doctors, nurses, pharmacists, and dentists. Avoid driving and doing other tasks or actions that call for you to be alert until you see how methsuximide affects you. Do not stop taking methsuximide all of a sudden without calling your doctor.
Methsuximide is used to control absence seizures (petit mal; a type of seizure in which there is a very short loss of awareness during which the person may stare straight ahead or blink his eyes and does not respond to others) that cannot be treated with other medications.
Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg, methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).
Ethosuximide was approved for medical use in the United States in 1960. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Ethosuximide is available as a generic medication. The wholesale cost in the developing world is about US$27.77 per month.
methsuximide (English) retrieved. 17 November 2016. DSSTOX substance identifier. DTXSID5023293. 1 reference. stated in. Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard. MeSH descriptor ID. C100286. 1 reference. stated in. Medical Subject Headings. MeSH descriptor ID. C100286.
Methsuximide may increase the excretion rate of 7,9-Dimethylguanine which could result in a lower serum level and potentially a reduction in efficacy. 8-azaguanine: Methsuximide may increase the excretion rate of 8-azaguanine which could result in a lower serum level and potentially a reduction in efficacy. 8-chlorotheophylline
methsuximide An antiepileptic used for absence seizures/petit mal epilepsy. Adverse effects Confusion, dizziness, drowsiness, headache, stomach ache, incoordination, anorexia, weight loss, nausea, vomiting, constipation, diarrhoea, insomnia. methsuximide Celontin® Neurology An antiepileptic used for absence seizures/petit mal epilepsy.
Methsuximide is used alone or in combination with other medications to treat absence seizures (also called "petit mal" seizures) in adults and children. Methsuximide may also be used for purposes not listed in this medication guide. Serious and sometimes fatal infections may occur during treatment with methsuximide.